Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 13;24(1):209.
doi: 10.1186/s12935-024-03386-2.

MicroRNA-98: the multifaceted regulator in human cancer progression and therapy

Vajihe Hazari  1 , Sahar Ahmad Samali  2 , Payam Izadpanahi  3 , Homa Mollaei  4 , Farzad Sadri  5   6 , Zohreh Rezaei  7   8
Affiliations
Review

MicroRNA-98: the multifaceted regulator in human cancer progression and therapy

Vajihe Hazari et al. Cancer Cell Int. .

Abstract

MicroRNA-98 (miR-98) stands as an important molecule in the intricate landscape of oncology. As a subset of microRNAs, these small non-coding RNAs have accompanied a new era in cancer research, underpinning their significant roles in tumorigenesis, metastasis, and therapeutic interventions. This review provides a comprehensive insight into the biogenesis, molecular properties, and physiological undertakings of miR-98, highlighting its double-edged role in cancer progression-acting both as a tumor promoter and suppressor. Intriguingly, miR-98 has profound implications for various aspects of cancer progression, modulating key cellular functions, including proliferation, apoptosis, and the cell cycle. Given its expression patterns, the potential of miR-98 as a diagnostic and prognostic biomarker, especially in liquid biopsies and tumor tissues, is explored, emphasizing the hurdles in translating these findings clinically. The review concludes by evaluating therapeutic avenues to modulate miR-98 expression, addressing the challenges in therapy resistance, and assessing the efficacy of miR-98 interventions. In conclusion, while miR-98's involvement in cancer showcases promising diagnostic and therapeutic avenues, future research should pivot towards understanding its role in tumor-stroma interactions, immune modulation, and metabolic regulation, thereby unlocking novel strategies for cancer management.

Keywords: MicroRNA-98; And biomarkers; Human cancers; Oncogenic; Tumor-suppressive.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The process of miRNA biogenesis. Pre-miRNAs are created after RNAPII transcribes miRNA genes to pri-miRNAs, which are ultimately produced when Drosha cleaves pri-miRNAs. Pre-miRNAs are transferred to the nucleus and into the cytoplasm via Exportin5, where Dicer will turn them into mature miRNAs. The combination of mature miRNAs with AGO2 creates RISCs, which are essential for regulating gene expression
Fig. 2
Fig. 2
(A) miR-98 family sequence structure. (B) It has two mature sequences, hsa-miR-98-5p (MIMAT0000096, miR-98-5p) and hsa-miR-98-3p (MIMAT0022842, miR-98-3p)
Fig. 3
Fig. 3
Comprehensive illustration of the interactions between miR-98 and its main target genes
Fig. 4
Fig. 4
A detailed overview of LncRNAs’ interactions with miR-98 in human malignancies
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pérez-Amado CJ, Bazan-Cordoba A, Hidalgo-Miranda A, Jiménez-Morales S. Mitochondrial heteroplasmy shifting as a potential biomarker of cancer progression. Int J Mol Sci. 2021;22(14):7369. doi: 10.3390/ijms22147369. - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Pajares MJ, Alemany-Cosme E, Goñi S, Bandres E, Palanca-Ballester C, Sandoval J. Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. Int J Mol Sci. 2021;22(14):7350. doi: 10.3390/ijms22147350. - DOI - PMC - PubMed
    1. Leite DJ, Ninova M, Hilbrant M, Arif S, Griffiths-Jones S, Ronshaugen M, et al. Pervasive microRNA duplication in chelicerates: insights from the embryonic microRNA repertoire of the spider Parasteatoda tepidariorum. Genome Biol Evol. 2016;8(7):2133–44. doi: 10.1093/gbe/evw143. - DOI - PMC - PubMed
    1. Mazziotta C, Cervellera CF, Lanzillotti C, Touzé A, Gaboriaud P, Tognon M, et al. MicroRNA dysregulations in Merkel cell carcinoma: molecular mechanisms and clinical applications. J Med Virol. 2023;95(1):e28375. doi: 10.1002/jmv.28375. - DOI - PubMed